Survodutide Efficacy:
- Achieved “statistically significant improvement” in 83% of patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis.
- Phase 2 trial demonstrated improvement without worsening of fibrosis stages F1, F2, and F3 after 48 weeks.
Clinical Significance:
- Positioned as a potential leading treatment for MASH, addressing significant unmet medical needs.
- Offers hope to patients with MASH and fibrosis, according to Dr. Arun Sanyal, principal investigator.
Trial Details:
- Double-blind, placebo-controlled trial involving 295 MASH patients with fibrosis stages 1-3.
- Weekly subcutaneous administration of survodutide, with dose escalation up to 6 mg.
Key Findings:
- More than 80% of patients on survodutide achieved significant improvement in MASH compared to 18% on placebo.
- Statistically significant improvement in liver fibrosis observed.
Future Directions:
- Survodutide may become a best-in-class treatment, with potential to impact interconnected cardiovascular, renal, and metabolic diseases.
- Phase 3 clinical trial program initiated for obesity.
Upcoming Presentations:
- Full data from the phase 2 trial to be presented in the coming months, further elucidating survodutide’s potential.